scholarly journals Modeling the dynamics of glucose, insulin, and free fatty acids with time delay: The impact of bariatric surgery on type 2 diabetes mellitus

2019 ◽  
Vol 16 (5) ◽  
pp. 5765-5787 ◽  
Author(s):  
Anarina L. Murillo ◽  
◽  
Jiaxu Li ◽  
Carlos Castillo-Chavez ◽  
◽  
...  
2011 ◽  
Vol 7 (3) ◽  
pp. 185-189 ◽  
Author(s):  
Richdeep S. Gill ◽  
Arya M. Sharma ◽  
David P. Al-Adra ◽  
Daniel W. Birch ◽  
Shahzeer Karmali

2018 ◽  
Vol 20 (11) ◽  
pp. 2661-2669 ◽  
Author(s):  
Sandro Spiller ◽  
Matthias Blüher ◽  
Ralf Hoffmann

2009 ◽  
Vol 33 (1) ◽  
pp. 56-57
Author(s):  
François N. Lauzière ◽  
Sébastien L. Ménard ◽  
Frédérique Frish ◽  
Pascal Brassard ◽  
Denis Cyr ◽  
...  

2018 ◽  
Vol 314 (2) ◽  
pp. H293-H310 ◽  
Author(s):  
Quincy A. Hathaway ◽  
Mark V. Pinti ◽  
Andrya J. Durr ◽  
Shanawar Waris ◽  
Danielle L. Shepherd ◽  
...  

Type 2 diabetes mellitus is a major risk factor for cardiovascular disease and mortality. Uncontrolled type 2 diabetes mellitus results in a systemic milieu of increased circulating glucose and fatty acids. The development of insulin resistance in cardiac tissue decreases cellular glucose import and enhances mitochondrial fatty acid uptake. While triacylglycerol and cytotoxic lipid species begin to accumulate in the cardiomyocyte, the energy substrate utilization ratio of free fatty acids to glucose changes to almost entirely free fatty acids. Accumulating evidence suggests a role of miRNA in mediating this metabolic transition. Energy substrate metabolism, apoptosis, and the production and response to excess reactive oxygen species are regulated by miRNA expression. The current momentum for understanding the dynamics of miRNA expression is limited by a lack of understanding of how miRNA expression is controlled. While miRNAs are important regulators in both normal and pathological states, an additional layer of complexity is added when regulation of miRNA regulators is considered. miRNA expression is known to be regulated through a number of mechanisms, which include, but are not limited to, epigenetics, exosomal transport, processing, and posttranscriptional sequestration. The purpose of this review is to outline how mitochondrial processes are regulated by miRNAs in the diabetic heart. Furthermore, we will highlight the regulatory mechanisms, such as epigenetics, exosomal transport, miRNA processing, and posttranslational sequestration, that participate as regulators of miRNA expression. Additionally, current and future treatment strategies targeting dysfunctional mitochondrial processes in the diseased myocardium, as well as emerging miRNA-based therapies, will be summarized.


Author(s):  
Ramsha Saman ◽  
Margaret Voila

Background: Dyslipidaemia is a major risk factor for cardiovascular complications in patients with type 2 diabetes mellitus and affects 10-73% of this population. In type 2 diabetes mellitus, increased efflux of free fatty acids from adipose tissue and impaired insulin mediated skeletal muscle uptake of free fatty acids, increases fatty acid flux to the liver and also decreased glucose utilization in muscle that leads to acute elevation of free fatty acids. Lipid profile which is altered in diabetes state is one of the significant factors in development of cardiovascular diseases. The derangements seen in serum lipid profile includes: increased total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL) and decreased high-density lipoprotein cholesterol (HDL) concentration. Hence with the aforementioned views the present study had been planned to evaluate the effect of atorvastatin and metformin combination therapy in type 2 diabetic dyslipidemias.Methods: Study design, observational prospective study, with duration of 4-5 months and sample size of 30 patients with type 2 diabetes mellitus are taken with mild to moderate dyslipidemias. The study subjects received combination therapy of metformin 500 mg/day along with atorvastatin 20mg/day, there effect is seen on serum lipid profile and fasting blood glucose levels (FBS).Results: There was a significant mean decrease in TC, LDL , TG , FBS by 31.7 mg/dl (p<0.05), 28.5 mg/dl (p value <0.05), 19.5 mg/dl (p<0.05), 9.13 mg/dl (p<0.05) respectively and rise in HDL by 1.7 mg/dl (p<0.05) ), no significant decrease in VLDL (p>0.05).Conclusions: Combination of atorvastatin and metformin was effective in reduction of TC, LDL, TG and FBS and elevation of HDL levels in type-2 diabetic dyslipidemias.


2019 ◽  
Vol 16 (2) ◽  
pp. 26-38
Author(s):  
A. J. AKAMO ◽  
R. N. UGBAJA ◽  
O. ADEMUYIWA ◽  
D. I. AKINLOYE ◽  
O. T. SOMADE ◽  
...  

Increase in plasma free fatty acids (FFAs) concentrations may cause cellular damage via the induction of oxidative stress. The aim of this present study was to investigate FFAs and oxidative stress in hypertension co-morbidly occurring with Type 2 Diabetes Mellitus (T2DM). Age and sex matched control subjects (n=150) and patients (n=470) [hypertensive nondiabetics (HND, n=179), normotensive diabetics (ND, n=132), hypertensive diabetics (HD, n=159)] presenting at the Medical Out-Patient Clinic of the State Hospital, Abeokuta, Nigeria were recruited. Fasting plasma glucose, creatinine, urea, FFAs, thiobarbituric acid reactive substances (TBARS) were determined spectrophotometrically. The presence of either or both diseases resulted in significant increase (p<0.05) in the plasma FFAs and oxidative stress marker-TBARS in different compartments (plasma, erythrocytes andlipoproteins) for both male and female patients when compared with their control counterparts. The increase in FFAs was more marked in comorbidity female when compared with other female patients. There was significant (p<0.05) difference in gender FFAs concentrations. In both controls and patients, FFAs in plasma are significantly (p<0.05) higher in male when compared with their female counterparts. This research revealed biochemical variations in hypertension co-morbidly occurring with T2DMcharacterised by gender-related elevation in FFAs and enhanced oxidative stress. Plasma FFAs might be a good biomarker predicting the occurrence and development of hypertension and/or T2DM.  


Sign in / Sign up

Export Citation Format

Share Document